Evan K. Day and colleagues discovered that sprouty2 (SPRY2), typically regarded as a tumor suppressor in certain cancers, actually facilitates tumor growth and resistance to receptor tyrosine kinase inhibitors in glioblastoma. Here, SPRY2 is linked to neoplasm.